The HDAC–Lactylation Axis in Cancer Chemoresistance: A Metabolic–Epigenetic Interface
- 1Department of Biochemistry, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea
- 2Department of Gynecology and Obstetrics, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea
- 3Department of Internal Medicine, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea
Abstract
Chemoresistance remains a critical obstacle in cancer therapy, shaped not only by genetic mutations but also by reversible metabolic and epigenetic adaptations. Enhanced glycolysis and lactate accumulation are associated with tumor fitness before and during therapy and position lactate as more than a metabolic byproduct, enabling it to act as a regulatory metabolite through lysine lactylation of histone and non-histone proteins. This review examines the HDAC–lactylation axis as a metabolic–epigenetic interface and asks whether HDAC-mediated regulation of lactylation causally influences chemotherapy resistance or sensitization. We summarize evidence on lactate production, protein lactylation in cancer, and class I histone deacetylases (HDAC1–3) as delactylases, highlighting the reversible nature of this modification. Current evidence implicates histone and non-histone lactylation in two processes relevant to chemotherapy response: histone lactylation-dependent transcriptional programs involved in metabolic stress responses and phenotypic plasticity, and direct regulation of non-histone proteins involved in DNA repair, RNA processing, genome stability, and cellular stress adaptation. Together, these findings suggest that the HDAC–lactylation axis functions as a dynamic metabolic–epigenetic regulatory network enabling context-dependent adaptive responses. HDAC isoform-focused pharmacological and genetic perturbation, inhibition of lactate dehydrogenase A (LDHA) or monocarboxylate transporter 1 (MCT1), suppression of monocarboxylate transporter 4 (MCT4), and site-specific lactylation proteomics using liquid chromatography–tandem mass spectrometry (LC-MS/MS) could clarify the contribution of this axis to chemotherapy response.
Related
- Divergent roles of H3K18 lactylation in human diseases: metabolic-epigenetic circuits and translational challenges
- A positive feedback loop of kynurenine-AhR-EMT upregulates tryptophan metabolic enzymes via epigenetic modification to facilitate immune escape in triple-negative breast cancer
- Metabolic regulation of ATM-KAT8-RPA1 axis in DNA damage repair and chemoresistance
- Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.
- Lactate dynamics at the Pseudomonas aeruginosa–host interface: bacterial metabolism, host defense, and emerging links to histone lactylation
BibTeX
@article{hoang2026hdaclactylation,
title = {{The HDAC–Lactylation Axis in Cancer Chemoresistance: A Metabolic–Epigenetic Interface}},
author = {Nhi Thi Tuyet Hoang and So-Jin Shin and Jin Young Kim and Ji Hae Seo},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272110000},
url = {https://www.mdpi.com/1422-0067/27/21/10000},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The HDAC–Lactylation Axis in Cancer Chemoresistance: A Metabolic–Epigenetic Interface
AU - Nhi Thi Tuyet Hoang
AU - So-Jin Shin
AU - Jin Young Kim
AU - Ji Hae Seo
PY - 2026
DA - 2026/11/08
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272110000
UR - https://www.mdpi.com/1422-0067/27/21/10000
AB - Chemoresistance remains a critical obstacle in cancer therapy, shaped not only by genetic mutations but also by reversible metabolic and epigenetic adaptations. Enhanced glycolysis and lactate accumulation are associated with tumor fitness before and during therapy and position lactate as more than a metabolic byproduct, enabling it to act as a regulatory metabolite through lysine lactylation of histone and non-histone proteins. This review examines the HDAC–lactylation axis as a metabolic–epigenetic interface and asks whether HDAC-mediated regulation of lactylation causally influences chemotherapy resistance or sensitization. We summarize evidence on lactate production, protein lactylation in cancer, and class I histone deacetylases (HDAC1–3) as delactylases, highlighting the reversible nature of this modification. Current evidence implicates histone and non-histone lactylation in two processes relevant to chemotherapy response: histone lactylation-dependent transcriptional programs involved in metabolic stress responses and phenotypic plasticity, and direct regulation of non-histone proteins involved in DNA repair, RNA processing, genome stability, and cellular stress adaptation. Together, these findings suggest that the HDAC–lactylation axis functions as a dynamic metabolic–epigenetic regulatory network enabling context-dependent adaptive responses. HDAC isoform-focused pharmacological and genetic perturbation, inhibition of lactate dehydrogenase A (LDHA) or monocarboxylate transporter 1 (MCT1), suppression of monocarboxylate transporter 4 (MCT4), and site-specific lactylation proteomics using liquid chromatography–tandem mass spectrometry (LC-MS/MS) could clarify the contribution of this axis to chemotherapy response.
SN - 1422-0067
ER -